Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311463 | 0.69 | GSK3B (0.32) | ALDH1A1 | |
| SCHEMBL29311492 | 0.69 | CA1 (0.37) | MAPTMGLLALDH1A1 | |
| SCHEMBL29311503 | 0.68 | ALDH1A1 (0.32) | MGLLALDH1A1 | |
| SCHEMBL29311487 | 0.66 | ALDH1A1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL19422100 | 0.65 | — | — | |
| SCHEMBL7604008 | 0.65 | — | — | |
| SCHEMBL29311484 | 0.61 | — | — | |
| SCHEMBL17030768 | 0.61 | CA12 (0.35) | MAPTMGLLKDM4EALDH1A1 | |
| SCHEMBL15360158 | 0.61 | MAPT (0.50) | MAPTKDM4EALDH1A1 | |
| SCHEMBL10059742 | 0.60 | ALDH1A1 (0.60) | MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | MAPT 3851/4885MGLL 229/4885KDM4E 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.